Melatonin phase-shifts human circadian rhythms with no evidence of changes in the duration of endogenous melatonin secretion or the 24-hour production of reproductive hormones by Rajaratnam, SMW et al.
Melatonin Phase-Shifts Human Circadian Rhythms with
No Evidence of Changes in the Duration of Endogenous
Melatonin Secretion or the 24-Hour Production of
Reproductive Hormones
SHANTHA M. W. RAJARATNAM, DERK-JAN DIJK, BENITA MIDDLETON, BARBARA M. STONE, AND
JOSEPHINE ARENDT
Centre for Chronobiology (S.M.W.R., D.-J.D., B.M., J.A.), School of Biomedical and Life Sciences, University of Surrey,
Guildford GU2 7XH, United Kingdom; Centre for Human Sciences (B.M.S.), QinetiQ Ltd., Farnborough GU14 0LX, United
Kingdom; and School of Psychology, Psychiatry and Psychological Medicine (S.M.W.R.), Monash University, Victoria 3800,
Australia
The pineal hormone melatonin is a popular treatment for
sleep and circadian rhythm disruption. Melatonin adminis-
tered at optimal times of the day for treatment often results in
a prolonged melatonin profile. In photoperiodic (day length-
dependent) species, changes in melatonin profile duration
influence the timing of seasonal rhythms. We investigated the
effects of an artificially prolonged melatonin profile on en-
dogenous melatonin and cortisol rhythms, wrist actigraphy,
and reproductive hormones in humans. Eight healthy men
took part in this double-blind, crossover study. Surge/sus-
tained release melatonin (1.5 mg) or placebo was administered
for 8 d at the beginning of a 16-h sleep opportunity (1600 h to
0800 h) in dim light. Compared with placebo, melatonin ad-
ministration advanced the timing of endogenous melatonin
and cortisol rhythms. Activity was reduced in the first half
and increased in the second half of the sleep opportunity with
melatonin; however, total activity during the sleep opportu-
nities and wake episodes was not affected. Melatonin treat-
ment did not affect the endogenous melatonin profile dura-
tion, pituitary/gonadal hormone levels (24-h), or sleepiness
and mood levels on the subsequent day. In the short term,
suitably timed sustained-release melatonin phase-shifts cir-
cadian rhythms and redistributes activity during a 16-h sleep
opportunity, with no evidence of changes in the duration of
endogenous melatonin secretion or pituitary/gonadal
hormones. (J Clin Endocrinol Metab 88: 4303–4309, 2003)
MELATONIN, AN INDOLEAMINE hormone, iswidely and indiscriminately used in countries in
which it is freely available for a variety of purposes including
the treatment of insomnia and combating jet lag. In 1996 it
was estimated that sales of melatonin in the United States
exceeded those of vitamin C, and apparently there was a
global shortage of the synthetic hormone (1).
Melatonin is synthesized and secreted by the pineal gland
mainly during the biological night, in both diurnal and noc-
turnal organisms (2). It is well established that in several
mammalian species the timing of melatonin synthesis, in
particular its duration, is used to organize seasonal functions
that respond to changes in day length (photoperiod) such as
reproduction (2). Although the rhythm of melatonin in hu-
mans has been shown to respond to changes in photoperiod
(3), the precise physiological role of melatonin in humans has
yet to be determined. This remains an important question
because administration of the hormone in doses frequently
used (2–5 mg) will normally result in a (artificially) pro-
longed melatonin profile.
Acute administration of melatonin during the daytime,
when endogenous concentrations are low, leads to an in-
crease in sleep propensity (4–12) and shifts in the timing of
the endogenous rhythm of melatonin (5, 13–16). Timed
chronic administration of melatonin to blind individuals, in
whom circadian rhythms are not synchronized to the exter-
nal light-dark cycle, can resynchronize these rhythms to the
24-h day (17, 18). These properties are potentially useful for
the treatment of circadian rhythm and sleep disorders. Ben-
eficial effects have indeed been reported in patients with
non-24-h sleep wake disorder and delayed sleep-phase syn-
drome, shift workers, and travelers suffering from jet-lag (12,
19–22). However, not all studies report phase-shifting effects
(23, 24), probably because of melatonin not being adminis-
tered at the correct circadian time.
The lack of consistency in currently available data and the
possible undesirable effects of chronic melatonin adminis-
tration on human endocrine function are major impediments
to the therapeutic applications of this hormone. We therefore
devised a protocol to establish unequivocally whether an
artificially prolonged melatonin profile does or does not
influence its own secretion, and that of other endocrine pa-
rameters in controlled conditions, with simultaneous wrist
activity recording and subjective assessments of mood and
sleepiness.
Subjects and Methods
Experimental subjects
Eight male subjects (body mass index 23.8  3.0 kg/m2; age 24.4 
4.4 yr), who were paid volunteers, were studied. Females were excluded
because this study required assessment of circadian phase on two oc-
Abbreviations: CR, Constant routine; CV, coefficient of variation; D,
study day; LD, limit of detection; PRL, prolactin.
0021-972X/03/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 88(9):4303–4309
Printed in U.S.A. Copyright © 2003 by The Endocrine Society
doi: 10.1210/jc.2003-030460
4303
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 07 October 2014. at 07:51 For personal use only. No other uses without permission. . All rights reserved.
casions approximately 10 d apart. Because body temperature rhythms
are substantially different between the follicular and luteal phase (25,
26), female volunteers were not included in this study in case this would
compromise the reliability of phase assessments.
Subjects were nonsmokers, unmedicated, and in good general health,
as determined by self-report, medical and sleep questionnaires, history
taking, physical examination, electrocardiography, and biochemical and
hematological screening tests. They had no history of psychiatric illness,
drug or alcohol dependence, sleep disorder, or recent shift work and
transmeridian travel. Maximum habitual caffeine and alcohol consump-
tion did not exceed 300 mg/d and 90 g/wk, respectively. Sleep was
assessed by polysomnography during a laboratory adaptation night.
The study was approved by the Defense Evaluation Research Agency
Centre for Human Sciences Ethics Committee (Farnborough, UK).
Design
The study had a double-blind, crossover design, balanced according
to the order of treatment. Subjects attended two 13-d trials (Fig. 1),
separated by at least 14 d. During each trial either melatonin (1.5 mg,
surge-sustained release, Penn Pharmaceuticals Ltd., Tredegar, Gwent,
UK) or placebo was administered orally in gelatin capsules for 8 con-
secutive days. The surge-sustained release preparation was specifically
designed for the purposes of the study to raise melatonin levels imme-
diately and then to maintain high levels until endogenous melatonin
secretion occurred. This ensured that circulating melatonin levels were
elevated throughout the 16-h sleep opportunity. The period of treatment
administration was chosen because although effects of melatonin on LH
secretion in men may be manifested rapidly (27), a significant reduction
was seen after 7 d of treatment with melatonin when using prolactin
(PRL) as an index of a photoperiodic response (28). Furthermore, 7 d of
treatment has been used in successful alleviation of jet lag symptoms
(29).
Protocol
The light-proof, sound-attenuated, temperature- and humidity-con-
trolled environmental scheduling facility (QinetiQ, Farnborough,
Hampshire, UK) consisted of individual bedrooms, communal living
and kitchen areas, showers, and lavatories. Ambient light was provided
by broad-spectrum fluorescent tubes (Osram Biolux, Langley, Berkshire,
UK). Throughout the study dim light was on average 2.4  0.1 lux
(mean  sem) in the angle of gaze and 5.0  0.2 lux looking directly at
the light. Before each session, subjects were instructed to abstain from
caffeine for 7 d and alcohol for 24 h and to maintain a regular sleep-wake
cycle (sleep 2300 h-0700 h) for 10 d. Adherence to the sleep-wake sched-
ule was verified by wrist actigraphy (Actiwatch-L, Cambridge Neuro-
technology, Cambridge, UK).
After an initial baseline sleep opportunity [day (D)1, 2300 h to 0715
h] in dim light, subjects underwent a constant routine (CR) for 29 h (CR1)
(D2–3, Fig. 1). During the CR, subjects were instructed to remain semi-
recumbent and awake in dim light and received identical nutrients every
2 h (30). Following the CR, subjects remained in bed in dim light during
daily scheduled 16-h sleep opportunities (D3-D11, 1600 h to 0800 h) with
knowledge of clock time but no access to recreational material such as
books and television. Light levels during wake episodes were 147.6 
4.3 lux in the angle of gaze. A standardized meal was provided each day
at 1300 h ( 1500 kJ), and light snacks were available at other times.
Melatonin or placebo was administered at 1600 h (D3-D10). On D11, all
subjects took placebo at 1600 h (single-blind). A second 29-h constant
routine (CR2) was imposed on D12-D13, followed by a 16-h recovery
sleep opportunity.
Outcome measures
Blood samples (2–4 ml) were collected into lithium-heparin contain-
ers via iv cannulae at 1-h intervals during the CRs to assess circadian
rhythm profiles and for 24 h on D3 to assess melatonin pharmacoki-
netics. Plasma was immediately separated by centrifugation and stored
at20 C. These samples were later assayed for melatonin, cortisol, PRL,
FSH, LH, testosterone, TSH, and GH.
Wrist activity levels were continuously measured throughout the
study using Actiwatch-L actigraphy monitors (Cambridge Neurotech-
nology). Computerized versions of the Karolinska Sleepiness Scale (31)
and a series of 12 subjective mood (visual analog) scales were admin-
istered at 2-h intervals during the wake episodes (0800 h-1400 h). The
mood scales reported here are as follows: agitation, concentration, ag-
gression, depression, and anxiety.
Other parameters recorded during the study were sleep via poly-
somnography during all scheduled sleep opportunities and CRs, tests of
cognitive performance during wake episodes and CRs, and core body
temperature during the entire study. These parameters will be reported
elsewhere.
Data analyses and statistics
Data are expressed as means  sem. Plasma melatonin and cortisol
concentrations were measured by RIA (Stockgrand Ltd., Guildford,
Surrey, UK). For the melatonin assay, the limit of detection (LD) was 6.5
pg/ml and the interassay coefficients of variation (CVs) were 14% at 27
pg/ml, 10% at 55 pg/ml, 13% at 145 pg/ml, and 13% at 244 pg/ml. For
the cortisol assay, the LD was 6.3 nmol/liter and the interassay CVs were
15% at 60 nmol/liter, 10% at 511 nmol/liter, and 8% at 918 nmol/liter.
Plasma samples obtained during CR2 were also assayed for pituitary/
gonadal hormones. PRL, FSH, LH, testosterone, and TSH concentrations
were measured by automated chemiluminescence (Bayer ACS 180,
Bayer Centaur, Newbury, Berkshire, UK), and GH concentrations were
measured by dissociation enhanced lanthanide fluoroimmunoassay
(Chemical Pathology Laboratory, Southampton University Hospitals
NHS Trust, Southampton, Hampshire, UK). The assay parameters were
as follows: CVs, PRL, 12.7%, 4.3%, and 6.0% at 93, 243, and 577 mU/liter;
LH, 5.5%, 6.8%, and 6.8% at 5.2, 19, and 40 IU/liter; GH, 8.8% at 1.12
mU/liter; TSH, 4.5%, 4.5%, and 4.5% at 0.65, 4.4, and 19 mU/liter;
testosterone, 10.4%, 4.2%, 5.1%, and 4.1% at 2.0, 3.3, 10.1, and 26.6
nmol/liter; and FSH, 5.4%, 7.7%, and 5.0% at 8.0, 24, and 57 IU/liter. LDs
were: PRL 6 mU/liter, LH 0.1 IU/liter, GH 0.1 mU/liter, TSH 0.01
mU/liter, testosterone 0.3 nmnol/liter, and FSH 0.3 IU/liter. Normal
reference ranges were PRL 150–500 mU/liter, LH 0.8–12.0 IU/liter, GH
0–5 mU/liter (fasting), TSH 0.35–5.5 mU/liter, testosterone 8.0–30.0
nmol/liter, and FSH 0.8–11.5 IU/liter. Reference ranges were derived
in-house except for TSH and testosterone in which values were derived
from the kit manufacturer.
Plasma samples collected during the first 4 h of the CR were excluded
to eliminate possible masking effects from the preceding sleep and
changes in posture. The onset and offset of the plasma melatonin rhythm
and the fitted maximum of the cortisol rhythm were used as markers of
the phase of the endogenous circadian pacemaker (32, 33). Peak levels
FIG. 1. Diagrammatic representation of study protocol for one treat-
ment trial. Successive days are shown beneath each other, and clock
time (24 h plotted from 1200 h) is shown on the horizontal axis. The
trial commenced at 1600 h on study D1 and ended at 0900 h on D14.
Scheduled sleep opportunities are represented in black, wake in
white, and CRs in gray. Treatment administration time (indicated by
downward-pointing arrows) was 1600 h from D3 to D11. On D11, all
subjects received a placebo capsule (indicated by upward-pointing
arrow) single blind.
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of plasma melatonin were calculated as the mean of the five highest
values for each subject. Melatonin onset and offset were defined as the
times corresponding to when plasma levels rose or declined to 25% of
the observed peak values, respectively. This method of determining
melatonin rhythm phase was selected to overcome problems with in-
dividual differences in melatonin secretion levels and was based on
previous studies (34, 35). Because of the episodic nature of the cortisol
rhythm profile, onset and offset measures would be obscured. Therefore,
the cortisol rhythm was quantified by cosinor analysis, a method used
in previous studies (36). Phase shifts were determined by calculating the
difference in timing of the melatonin onset and cortisol peak in CR1 and
CR2. The duration of high plasma melatonin was defined as the number
of hours between melatonin onset and melatonin offset.
Data were statistically analyzed by repeated measures ANOVA or
paired samples t test, as appropriate. Where ANOVA was applied, a full
model was used and main effects and interaction effects were included.
For plasma melatonin and cortisol phase markers, two-way ANOVA
was carried out with factors treatment trial and CR. For wrist actigraphy
and subject mood and sleepiness assessments, two-way ANOVA was
applied with factors treatment trial and time of day. P  0.05 was used
to determine significance. Significant effects revealed by ANOVA were
subjected to post hoc analysis using paired samples t test. Statistical
analyses were performed using either the SAS (version 8.0, SAS Institute
Inc., Cary, NC) or SPSS (version 10.05, SPSS Inc., Chicago, IL) statistical
software packages.
Results
Melatonin pharmacokinetics
On the first day of melatonin administration (D3), plasma
melatonin levels rose rapidly in the first hour to, on average,
431  135 pg/ml (maximum 626  212 pg/ml, 3 h post
administration) and remained elevated above the placebo
nocturnal values for the duration of the sleep opportunity
(Fig. 2).
Melatonin and cortisol rhythms
During the initial circadian phase assessments (CR1), all
subjects exhibited normal 24-h profiles of plasma melatonin
and cortisol during both treatment trials (Figs. 3 and 4).
The timing of melatonin onset and the cortisol peak were
significantly advanced after both melatonin (5.3 h and 4.4 h,
respectively, P  0.01) and placebo (2.4 h and 1.8 h, respec-
tively, P 0.05) treatment. However, the advances following
melatonin were significantly greater than after placebo (P 
0.05; Table 1).
In CR1, the duration of high plasma melatonin was 9.0 
0.6 h and 9.5  0.4 h in the melatonin and placebo trials,
respectively. The duration of high melatonin in CR2 was
identical in the melatonin and placebo trials (8.9 0.5 h). No
significant change was observed from CR1 to CR2 in either
trial.
Wrist actigraphy
Mean activity levels at hourly intervals, as determined by
wrist actigraphy, were calculated for sleep opportunities of
all treatment administration days except D3. Data from D3
were excluded because of the possible influence of the period
of extended wakefulness associated with CR1. Mean activity
levels were higher in the placebo trial than in the melatonin
trial during the first half of the sleep opportunity and lower
in the placebo trial than in the melatonin trial during the
second half of the sleep opportunity (Fig. 5). A significant
treatment trial by time interaction was observed (P 0.001).
Post hoc analysis revealed that between 1900 h and 2300 h,
FIG. 2. Mean (SEM) plasma melatonin concentrations (pg/ml) 1 h
before and 23 h after the first administration of the melatonin (closed
circles) and placebo (open circles) treatments. Clock time is shown on
the horizontal axis, and the vertical arrow indicates the time of treat-
ment administration (1600 h). The two dashed lines represent the
beginning and end of the scheduled sleep opportunity.
FIG. 3. Mean (SEM) profiles of plasma melatonin
and plasma cortisol for the placebo trial (left) and
melatonin trial (right), in CR1 (closed circles) and CR2
(open circles). Clock time is shown on the horizontal
axis. Data are double-plotted (i.e. 24-h data are plot-
ted twice) for clarity, and the double-plot segment is
indicated by a vertical dashed line and the absence of
error bars.
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activity levels during the placebo trial were significantly
greater than during the melatonin trial (P  0.05), and be-
tween 0200 h and 0300 h activity levels were significantly
higher in the melatonin trial (P  0.05).
Mean total activity levels calculated across the treatment
period (D4 to D10) for the sleep opportunities and the sched-
uled wake episodes separately did not differ between the
melatonin and placebo trials (P  0.05; Fig. 6).
Pituitary/gonadal hormones
Mean 24-h levels of pituitary/gonadal hormones, assessed
during CR2, were found to be within normal range (37) in
both treatment trials (Table 2), except for one subject, who
showed abnormally high TSH levels in both trials (5 sds
from mean values). This subject’s TSH data were excluded
from the analysis. Average levels of all hormones measured
did not vary significantly between the treatment trials (Table
2). Although there was no significant difference in PRL levels
between the two trials, the level after melatonin treatment
was slightly lower than after placebo (difference 18.3 mU/
liter; P  0.07, 95% confidence interval 38.9 to 2.3).
Self-assessment of daytime sleepiness and mood
As for the actigraphy analysis, data from D3 were ex-
cluded for self-assessed sleepiness and mood. There was not
a significant effect of melatonin administration on daytime
sleepiness or mood scores (D4-D11, Table 3). A main effect
of time of day was found for sleepiness scores (P  0.001),
with scores at 0800 h being significantly higher than other
times.
Discussion
The present study provides clear and convincing evidence
that melatonin (1.5 mg at 1600 h) is able to substantially
advance the timing of endogenous melatonin and cortisol
rhythms with no evidence of changes in the duration of
endogenous melatonin secretion or changes in the pituitary/
gonadal axis. Actigraphic data indicate that the distribution
of activity was profoundly altered during melatonin admin-
istration such that lower activity occurred during the first
half of the sleep opportunity after melatonin and during the
second half after placebo. However, total activity levels dur-
ing the scheduled sleep opportunities and during the wake
episodes were not altered by melatonin administration. Sim-
ilarly, daytime sleepiness and mood were not affected.
The magnitude of the phase advances induced by mela-
tonin are consistent with previous reports (5, 13–15). Small
phase advances were also observed in the placebo trial, and
these are likely to be caused by the alteration in light/dark
exposure, in particular the lack of high light levels during the
evening (38) and possibly the daily regimen of enforced bed
TABLE 1. Circadian phase shifts
Melatonin
trial Placebo trial
95% CI
CR1 vs. CR2
95% CI
Mel vs. Plac
Plasma melatonin onseta 5.3 h (0.4)d 2.4 h (0.7)c Mel: 4.3 to 6.2 0.6 to 5.2
Plac: 0.7 to 4.0
Plasma cortisol peakb 4.4 h (0.5)d 1.8 h (0.5)c Mel: 3.2 to 5.5 1.1 to 4.1
Plac: 0.7 to 2.9
Mean (SEM) phase shifts (h) observed for plasma melatonin onset (25% crossing) and cortisol peak. Positive values indicate advances in
the timing of the phase marker from constant routine (CR)1 to CR2. These data were analyzed by 2-way repeated measures ANOVA (factors,
treatment trial and CR). ANOVA revealed significant main effects for CR (melatonin onset P  0.001; cortisol peak P  0.001) and significant
treatment trial CR interaction effects (melatonin onset P 0.05; cortisol peak P 0.01). These interactions were further analyzed by paired
samples t tests. Significant differences in the magnitude of shifts between the melatonin (Mel) and the placebo (Plac) trial are indicated as a
if P  0.05 and b if P  0.01. Significant advances from CR1 to CR2 are shown as c if P  0.05 and d if P  0.01. For each comparison (CR1
vs. CR2, or Mel vs. Plac), the 95% confidence interval (CI) for the difference is shown.
FIG. 4. Plasma melatonin profiles for individual subjects (s1, s3, s5,
s7, s10, s28, s29, and s30) in the placebo trial (left) and melatonin trial
(right), in CR1 (closed circles) and CR2 (open circles). The vertical axis
represents plasma melatonin levels (exact values not given), and clock
time (h) is shown on the horizontal axis.
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rest. Melatonin evidently reinforced the effects observed in
the placebo condition.
The redistribution of wrist activity levels by melatonin
administration occurred without altering the total activity
levels during the sleep opportunities or the wake episodes.
These findings are in contrast to those of Zhdanova et al. (39),
who showed that melatonin (40–320 g/kg) administered to
three species of nonhuman primates resulted in increased
nocturnal (actigraphically assessed) activity levels and re-
duced daytime activity levels. A number of methodological
differences between the previous study and present study
may account for the divergent findings, including species;
light-dark and activity-rest cycles; whether there was en-
forced recumbency during melatonin treatment; and the tim-
ing, dose, and formulation of melatonin.
Artificially prolonged melatonin profiles usually occur in
protocols that use melatonin as a phase-shifting agent be-
cause to achieve maximal shifts, the optimal time of admin-
istration will be several hours before or after the time when
endogenous melatonin levels are high (40). It is therefore
important to ascertain whether a prolonged melatonin pro-
file results in altered circadian and pituitary/gonadal func-
tioning in humans, as is the case in many seasonally breeding
mammals (2). Prolonged exposure of human subjects to a
long-night, short-day cycle results in changes in the profile
of some circadian rhythms including the melatonin rhythm
and slightly increased duration and redistribution of sleep (3,
41). These findings are reminiscent of the effects of photo-
period in other mammalian species (42, 43). In our study, 9 d
of exposure to 16-h sleep opportunities did not produce
photoperiodic changes in melatonin duration. Comparing
these data with those of Wehr and colleagues (3), it may be
suggested that the length of time required to observe human
photoperiodic responses is between 9 d and 4 wk. Alterna-
tively, it is possible that the sample size used in the present
study was not sufficient to detect statistically significant hu-
man photoperiodic responses.
In this short-term study of the effects of an artificially
prolonged melatonin profile, we did not observe changes in
the duration of endogenous melatonin and found no signif-
icant changes in 24-h levels of pituitary/gonadal hormones.
A previous study showed that long-term melatonin admin-
istration (1 month, 6 mg) to six healthy male subjects did not
alter mean nocturnal LH, FSH, testosterone, and inhibin-
secretion (44). The trend to lower PRL after melatonin treat-
ment in the present study may, however, indicate a compa-
rable photoperiodic response in humans should treatment be
prolonged. PRL declines rapidly under short days (or long
duration melatonin) in photoperiodic species (45). The non-
significant decline in PRL observed in the present study is if
anything reassuring because increased PRL is associated
with a number of problems including infertility in women
(46), with some evidence for such an association in men (47).
A surge-sustained release capsule containing melatonin
(1.5 mg) was used in the present study to achieve high cir-
culating levels for at least the duration of the sleep oppor-
tunity (16 h) at close to physiological levels. Whether the
concentrations achieved using this formulation of melatonin
(maximum 626  212 pg/ml) could be considered a phar-
macological or a physiological treatment is a matter for dis-
cussion, and further data are required on the concentration
of melatonin at its target sites (48).
Our findings that melatonin administration does not have
deleterious effects on subjective assessments of daytime
sleepiness and mood on the day following treatment support
the short-term use of melatonin for the treatment of sleep
complaints. Particularly in situations in which the circadian
clock is misaligned from external time cues, e.g. after rapid
time zone change and when employed on changing shift
TABLE 2. Pituitary/gonadal hormone concentrations
Melatonin
trial Placebo trial
PRL (mU/liter) 230.64 (9.33) 248.93 (15.09)
LH (IU/liter) 4.28 (0.41) 4.58 (0.70)
GH (mU/liter) 2.14 (0.39) 2.57 (0.81)
TSH (mU/liter) 2.94 (0.36) 3.03 (0.39)
Testosterone (nmol/liter) 18.83 (1.75) 18.54 (1.25)
FSH (IU/liter) 3.69 (1.32) 3.83 (1.41)
Mean (SEM) 24-h pituitary/gonadal hormone levels assessed dur-
ing CR2 in the melatonin and placebo trials. Hormone levels were
measured hourly for 24 h, and mean levels were determined. Admin-
istration of melatonin (1.5 mg) for 8 consecutive days did not signif-
icantly alter any of the hormone levels.FIG. 5. Mean (SEM) wrist activity levels (1-h intervals) recordedduring sleep opportunities calculated across all treatment days except
study D3 in the melatonin trial (closed circles) and the corresponding
day of the placebo trial (open circles). Clock time is shown on the
horizontal axis. Significant differences between the melatonin and
placebo trials, revealed by repeated-measures ANOVA and subse-
quent paired samples t tests, are indicated by asterisks (P  0.05).
FIG. 6. Mean (SEM) total wrist activity levels during scheduled
sleep opportunities and wake episodes, calculated across all treat-
ment days except study D3 in the melatonin trial (black columns) and
the corresponding day of the placebo trial (white columns). Paired
samples t tests did not reveal significant differences between the
treatment trials (P  0.05).
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schedules (49), melatonin administration, under appropriate
conditions, may have substantial benefits. Non-24-h sleep-
wake disorder of the blind is a lifetime problem requiring
long-term treatment. Melatonin is probably the treatment of
choice in these patients (17, 18). In this case long-term safety
studies are desirable (50), and the present findings should be
confirmed in clinical populations. We also note that if desired
sleep time is not for several hours after the time of melatonin
administration (e.g. 1600 h), alertness levels may be compro-
mised during the intervening period.
In summary, these findings provide unequivocal evidence
that, in the short term, timed melatonin treatment in suitable
conditions is a highly effective means of phase-shifting cir-
cadian rhythms, without indication of deleterious effects on
major aspects of human endocrine function, or daytime
sleepiness and mood on the day following administration.
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